

# Daniel L Jacoby

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6789353/publications.pdf>

Version: 2024-02-01

82  
papers

4,238  
citations

147801

31  
h-index

123424

61  
g-index

84  
all docs

84  
docs citations

84  
times ranked

4684  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 759-769.	13.7	481
2	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2018, 138, 1387-1398.	1.6	468
3	Empagliflozin in Heart Failure. <i>Circulation</i> , 2020, 142, 1028-1039.	1.6	252
4	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Circulation</i> , 2020, 141, 1872-1884.	1.6	229
5	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2020, 141, 828-842.	1.6	181
6	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2649-2660.	2.8	176
7	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 12-21.	4.1	152
8	Genetics of inherited cardiomyopathy. <i>European Heart Journal</i> , 2012, 33, 296-304.	2.2	146
9	Update on hypertrophic cardiomyopathy and a guide to the guidelines. <i>Nature Reviews Cardiology</i> , 2016, 13, 651-675.	13.7	110
10	Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002370.	3.9	109
11	Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2021, 143, 606-608.	1.6	109
12	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2467-2475.	13.7	98
13	Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 660-668.	7.1	94
14	Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated Heart Failure Treatment. <i>American Journal of Medicine</i> , 2015, 128, 776-783.e4.	1.5	88
15	Anisotropic engineered heart tissue made from laser-cut decellularized myocardium. <i>Scientific Reports</i> , 2016, 6, 32068.	3.3	74
16	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 1988-1996.	2.2	69
17	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. <i>Circulation</i> , 2021, 143, 1852-1862.	1.6	65
18	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. <i>JACC: Heart Failure</i> , 2021, 9, 420-429.	4.1	64

#	ARTICLE	IF	CITATIONS
19	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. <i>JAMA Cardiology</i> , 2020, 5, 83.	6.1	60
20	Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 199-208.	4.1	59
21	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2518-2532.	2.8	59
22	Application of Whole Exome Sequencing in the Clinical Diagnosis and Management of Inherited Cardiovascular Diseases in Adults. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	55
23	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2017, 135, 1882-1893.	1.6	53
24	Study Design and Rationale of EXPLORER-HCM. <i>Circulation: Heart Failure</i> , 2020, 13, e006853.	3.9	48
25	Spatial and Functional Distribution of <i>MYBPC3</i> Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 396-405.	3.6	47
26	Incident Atrial Fibrillation Is Associated With <i>MYH7</i> Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e005191.	3.9	46
27	Extracellular Matrix From Hypertrophic Myocardium Provokes Impaired Twitch Dynamics in Healthy Cardiomyocytes. <i>JACC Basic To Translational Science</i> , 2019, 4, 495-505.	4.1	46
28	Feasibility and Efficacy of a Self-Management Intervention for Insomnia in Stable Heart Failure. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 1109-1119.	2.6	45
29	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 3932-3944.	2.2	43
30	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. <i>Circulation</i> , 2018, 138, 1210-1220.	1.6	42
31	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. <i>Genetics in Medicine</i> , 2021, 23, 69-79.	2.4	39
32	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003062.	3.6	38
33	Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. <i>Cmaj</i> , 2013, 185, 127-134.	2.0	34
34	Effects of Cognitive Behavioral Therapy for Insomnia on Sleep, Symptoms, Stress, and Autonomic Function Among Patients With Heart Failure. <i>Behavioral Sleep Medicine</i> , 2020, 18, 190-202.	2.1	34
35	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. <i>PLoS ONE</i> , 2016, 11, e0145881.	2.5	30
36	Cognitive behavioral therapy for insomnia has sustained effects on insomnia, fatigue, and function among people with chronic heart failure and insomnia: the HeartSleep Study. <i>Sleep</i> , 2022, 45, .	1.1	30

#	ARTICLE	IF	CITATIONS
37	Cognitive behavioral therapy for insomnia in stable heart failure: Protocol for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2017, 55, 16-23.	1.8	29
38	Automated multilabel diagnosis on electrocardiographic images and signals. <i>Nature Communications</i> , 2022, 13, 1583.	12.8	29
39	Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. <i>Journal of Cardiac Failure</i> , 2018, 24, 131-133.	1.7	28
40	Influence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002333.	3.9	25
41	Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation. <i>JCI Insight</i> , 2019, 4, .	5.0	25
42	Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6. <i>European Journal of Heart Failure</i> , 2018, 20, 933-934.	7.1	24
43	Improving Outcomes in INTERMACS Category 1 Patients with Pre-LVAD, Awake Venous-Arterial Extracorporeal Membrane Oxygenation Support. <i>ASAIO Journal</i> , 2019, 65, 819-826.	1.6	22
44	Effects of Cognitive Behavioral Therapy for Insomnia on Sleep-Related Cognitions Among Patients With Stable Heart Failure. <i>Behavioral Sleep Medicine</i> , 2019, 17, 342-354.	2.1	20
45	Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2022, 145, 1238-1253.	1.6	20
46	Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1309-1318.	1.5	19
47	Familial dilated cardiomyopathy diagnosis is commonly overlooked at the time of transplant listing. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 474-480.	0.6	18
48	Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium. <i>Journal of the American Heart Association</i> , 2021, 10, e020860.	3.7	18
49	Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. <i>Journal of General Physiology</i> , 2021, 153, .	1.9	15
50	Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System. <i>JAMA Network Open</i> , 2020, 3, e2017513.	5.9	14
51	The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft Survival: Insights Into Reno-Cardiac Interactions. <i>Journal of Cardiac Failure</i> , 2016, 22, 368-375.	1.7	11
52	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. <i>PLoS ONE</i> , 2021, 16, e0247789.	2.5	11
53	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. <i>Genetics in Medicine</i> , 2021, 23, 1281-1287.	2.4	11
54	Evaluating Recruitment Strategies for a Randomized Clinical Trial with Heart Failure Patients. <i>Western Journal of Nursing Research</i> , 2020, 43, 019394592097022.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Impact of Obesity on Heart Transplantation Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e021346.	3.7	10
56	Psychological stress in heart failure: a potentially actionable disease modifier. <i>Heart Failure Reviews</i> , 2021, 26, 561-575.	3.9	9
57	Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in a young female athlete at 36 weeks gestation: a case report. <i>Pathology Research and Practice</i> , 2017, 213, 1302-1305.	2.3	8
58	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. <i>International Journal of Cardiology</i> , 2019, 290, 100-105.	1.7	8
59	Perceived Stress, Subjective, and Objective Symptoms of Disturbed Sleep in Men and Women with Stable Heart Failure. <i>Behavioral Sleep Medicine</i> , 2021, 19, 363-377.	2.1	8
60	Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3™. <i>ASAIO Journal</i> , 2022, 68, 374-383.	1.6	8
61	Symptom Cluster Profiles Among Adults with Insomnia and Heart Failure. <i>Behavioral Sleep Medicine</i> , 2023, 21, 150-161.	2.1	8
62	The Genetic Challenges and Opportunities in Advanced Heart Failure. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1338-1350.	1.7	7
63	Day-to-day Relationships between Physical Activity and Sleep Characteristics among People with Heart Failure and Insomnia. <i>Behavioral Sleep Medicine</i> , 2021, 19, 602-614.	2.1	6
64	Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. <i>American Heart Journal</i> , 2022, 246, 21-31.	2.7	6
65	Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 777-785.	4.7	5
66	Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. <i>European Journal of Internal Medicine</i> , 2022, 102, 1-7.	2.2	5
67	Sleep Characteristics, Mood, Somatic Symptoms, and Self-Care Among People With Heart Failure and Insomnia. <i>Nursing Research</i> , 2022, 71, 189-199.	1.7	4
68	Mulibrey Nanism Syndrome: A Case for Heart Transplantation. <i>Annals of Thoracic Surgery</i> , 2020, 109, e115-e117.	1.3	3
69	Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. <i>Preventive Medicine Reports</i> , 2020, 18, 101085.	1.8	3
70	Differential Impact of Class I and Class II Panel Reactive Antibodies on Post-Heart Transplant Outcomes. <i>Journal of Cardiac Failure</i> , 2021, 27, 40-47.	1.7	3
71	Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. <i>ASAIO Journal</i> , 2021, 67, 650-657.	1.6	3
72	The Yale Roadmap for Health Psychology and Integrated Cardiovascular Care.. <i>Health Psychology</i> , 2022, 41, 779-791.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. <i>Cardiology Clinics</i> , 2011, 29, 485-495.	2.2	2
74	Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply. <i>Lancet</i> , The, 2021, 397, 369-370.	13.7	2
75	Novel Myosin-Based Therapies in Hypertrophic Cardiomyopathy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.9	2
76	When the money is not in the bank. <i>European Heart Journal</i> , 2016, 37, 1847-1849.	2.2	1
77	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. <i>American Heart Journal</i> , 2019, 214, 28-35.	2.7	1
78	The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic <i>transthyretin</i> expression. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 110-119.	3.0	1
79	Placing heart failure and diastolic dysfunction in the case of cardiac amyloid into perspective: what an amyloid heart really looks like. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 543-544.	1.5	0
80	Advanced Cardiac Imaging and the Complexity of Diagnosing Cardiac Sarcoidosis. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009275.	2.6	0
81	342 CBT-I Has Sustained Effects on Insomnia Versus Heart-Failure Self-Management Education among Adults with Chronic Heart Failure. <i>Sleep</i> , 2021, 44, A136-A137.	1.1	0
82	Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction.. <i>Blood</i> , 2010, 116, 1309-1309.	1.4	0